UBS Maintains Buy on AnaptysBio, Lowers Price Target to $60

Benzinga Newsdesk www.benzinga.com Neutral 55.1%

Neg 0% Neu 55.1% Pos 0%

UBS analyst Michael Yee maintains AnaptysBio (NASDAQ:ANAB) with a Buy and lowers the price target from $90 to $60.

Comments

No comments yet. Be the first!